Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839060 | 0.79 | LTB4R (0.32) | LTB4R | |
| SCHEMBL8935762 | 0.79 | KMT2A (0.43) | MCL1ALDH1A1TP53MAPTPOLB | |
| SCHEMBL8765283 | 0.78 | MCL1 (0.45) | MCL1LTB4RALDH1A1MAPK1TP53 | |
| SCHEMBL8755383 | 0.78 | ALDH1A1 (0.40) | LTB4RALDH1A1MAPK1MAPTPOLB | |
| SCHEMBL13997749 | 0.77 | LTB4R (0.39) | MCL1LTB4RALDH1A1MAPT | |
| SCHEMBL13217240 | 0.76 | MCL1 (0.42) | MCL1LTB4RALDH1A1SMN1; SMN2 | |
| SCHEMBL8601997 | 0.74 | ALDH1A1 (0.44) | ALDH1A1MAPK1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL8596932 | 0.74 | MCL1 (0.41) | MCL1LTB4RALDH1A1SMN1; SMN2 | |
| SCHEMBL13997750 | 0.74 | LTB4R (0.41) | LTB4RALDH1A1MAPTAOC3 | |
| SCHEMBL9594349 | 0.74 | LTB4R (0.41) | LTB4RALDH1A1MAPTAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282581-B2 | Oligonucleotide labeling reactants based on acyclonucleosides and conjugates derived thereof | WALLAC OY (FI) | 2007-10-16 | — | — | US | disclosed |
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | HOVINEN JARI (FI) | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040260080-A1 | Oligonucleotide labeling reactants and their use | SSU72, LIG4, NSUN2 | MCL1 1773/4885SLC6A3 3665/4885LTB4R 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.